RNA Based Therapeutics Market is expected to garner $1.2 billion by 2020, registering a CAGR of 28.4% during the forecast period 2014 – 2020. The Global RNA based therapeutics Market has garnered significant attention in the recent years due to its potential to treat variety of chronic diseases such as cancer, diabetes, AIDS, Tuberculosis and certain cardiovascular conditions.

RNA based therapeutics have wide applications covering variety of chronic conditions such as Cardiovascular, Kidney Diseases, Oncology, Infectious diseases, Metabolic disorders and Others. The pipeline research is concentrated towards oncology and infectious diseases due to their high prevalence and failure of existing treatment to effectively treat these conditions. The end user market is segmented into research, therapeutics and diagnostics. Currently, research and diagnostics segments are largely exploring the RNA technologies and therapies for the commercialization of RNA drugs.

Get sample copy of this report at:
www.alliedmarketresearch.com/request-sample/546

Despite being in the clinical research phase, the RNA based therapeutics is been explored as a promising treatment option for the diseases which are difficult to treat.Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology and SMaRT technology. RNAi technology and antisense technology together are gaining prominence in the research industry, as these technologies provide base sequence to develop RNA drugs. RNAi technology works by causing destruction of specific mRNA molecules; whereas, antisense technology works by synthesizing strand of RNA from known gene sequence. These newly synthesized RNA strands then itself binds to mRNA and make mRNA inactive. Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market. The other drivers include target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, critical issues in drug delivery, high cost of research, and high failure rates are some of the major hurdles for the companies working in this field.

Get customized copy of this report at:
www.alliedmarketresearch.com/request-for-customization/546

Key players in the market:

• Quark Pharmaceuticals Inc. (USA)
• Alnylam Pharmaceuticals Inc. (USA)
• Dicerna Pharmaceuticals Inc. (USA)
• Tekmira Pharmaceuticals Corp. (Canada)
• Benitec Biopharma Limited (Australia)
• Genzyme Corporation (USA)
• ISIS pharmaceuticals Inc (USA)
• Silence Therapeutics PLC (UK)
• Cenix BioScience GmbH (Germany)

Geographically, RNA based therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. Potential regions of the respective geographies are strategically analyzed to provide country wise focus on RNA research activities. North America dominates the RNA based therapeutics followed by Europe and Asia-Pacific. The key market players belong to North America and are conducting extensive research to commercialize the therapeutics. Moreover, the growth in North America and Europe is primarily driven by substantial investment on research, advancement in RNA platform technologies, government support and availability of suitable infrastructure to develop the novel RNA based therapies. However, business dynamics in Asia-pacific is anticipated to offer tremendous opportunities to major players of this market as cost of clinical research is less in this region as compared to North America and Europe.

Table of content : 

Chapter: 1 INTRODUCTION

1.1 Report Description
1.2 Reason for doing the study
1.3 Key Benefits
1.4 Key Market Segments
1.5 Key Audiences
1.6 Research Methodology

1.6.1 Secondary Research
1.6.2 Primary Research
1.6.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective
2.2 Market beyond what to expect by 2025

2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

Chapter: 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Historical perspective and current market trends
3.3 SMaRT RNA Technology- A promising Tool To Target Disease Causing RNAs
3.4 Conventional Vs RNA-based therapeutics
3.5 Addressable Market Analysis

3.5.1 DNA based therapeutics
3.5.2 RNA based thearpeutics

3.6 Key Findings

3.6.1 Top Factors Impacting on RNA based therapeutics market
3.6.2 Top Investment Pockets of RNA based therapeutics market
3.6.3 Top winning strategies of RNA based therapeutics market

3.7 Government Regulations

3.7.1 USFDA Perspective
3.7.2 European Union Perspective

3.8 Porter five force model

3.8.1 Bargaining power of buyers (Low)
3.8.2 Bargaining power of suppliers(High)
3.8.3 Threat of new entrants (High)
3.8.4 Threat of substitute products (Moderate)
3.8.5 Intensity of competitive rivalry (Strong)

3.9 Value chain analysis

3.9.1 Primary activities
3.9.2 Support Activities

3.10 Pipeline Review
3.11 Patent Analysis

3.11.1 Patent analysis by geographies(2010-2014)

3.12 Clinical Trials For RNA Based Therapeutics
3.13 Market Dynamics

3.13.1 Drivers

3.13.1.1 Target specificty and selectivity of treatment
3.13.1.2 Strategic Alliances and Funding
3.13.1.3 More intense product focus against platform technology
3.13.1.4 Promising technologies driving the RNA based therapeutics
3.13.1.5 Adoption of virtual drug development models

3.13.2 Restraints

3.13.2.1 Hurdles in drug delivery
3.13.2.2 High cost of research and threat of failure

3.13.3 Opportunities

3.13.3.1 Early commercialization of pipeline therapeutics assists to gain competitive advantage
3.13.3.2 Multifactorial disease targeting

Access more information at:
www.alliedmarketresearch.com/rna-based-therapeutics-market

Tags: RNA Based Therapeutics Market Growth, RNA Based Therapeutics Market share, RNA Based Therapeutics Market Size